Injectable “satellite livers” could offer an alternative to liver transplantation
March 3, 2026
The engineered tissue grafts could take on the liver’s function and help thousands of people with liver failure.
The engineered tissue grafts could take on the liver’s function and help thousands of people with liver failure.
OSLO, Norway, March 3, 2026 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.
LILSE, Ill., March 3, 2026 /PRNewswire/ — Hubly Surgical has been awarded a Breakthrough Technology Designation for Neurosurgical Products with Premier, Inc. Premier offers Breakthrough Technology designations to innovations that offer a major advantage in terms of patient safety, clinical outcomes and operational efficiencies.
TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.
A new, fully customizable 3D printed socket design is set to transform the prosthetics industry.
In tests on mice, we delivered a special enzyme to tumors and used a fluorescence probe that only turns on when that enzyme is present,
A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.
A wearable device that alerts people with food allergies before a reaction begins has the potential to reduce life-threatening anaphylaxis and transform allergy management from reactive to preventive care.
Scientists at Duke-NUS Medical School have identified a molecular “switch” that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some of the most treatment-resistant tumors into forms that are more manageable with existing drugs.
Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have developed the first bandage-like microneedle patch that can sample the body’s immune responses painlessly from the skin.